The Europe Cardiac Biomarkers Testing Market would witness market growth of 11.1% CAGR during the forecast period (2019-2025). The ability of cardiac markers for accurate and rapid prediction of heart failure after the onset of chest pain has added a boost to market growth. Additionally, promising features like high accuracy, quick outcomes, and economic pricing of cardiac point of care (POC) testing is further driving the growth of the market across the globe. To keep the momentum of cardiac marker tests, the key manufacturers offer customized solutions. The commercial application of multi-menu options, which are meant for cardiac testing done through different combinations of cardiac biomarkers and target-oriented solutions, are the major opportunities of the market. However, limited specificity in some cases and side effects such as skeletal muscle injury is restraining the growth cardiac biomarkers markets.
Based on Type, the market is segmented into Creatine Kinase (CK-MB), Troponins, Myoglobin, Natriuretic Peptides (BNP and NT-proBNP), Ischemia Modified Albumin and Others. Based on Application, the market is segmented into Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis and Others. Based on Location of Testing, the market is segmented into Point of Care Testing and Laboratory Testing. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Trivitron Healthcare Pvt. Ltd., ABBOTT Laboratories, Siemens AG, Becton, Dickinson AND Company, Bio-Rad laboratories, Inc., Randox Laboratories Limited, Danaher Corporation, Thermo Fisher Scientific, Inc., Johnson and Johnson and Quidel Corporation.
Market Segmentation:
By Type
By Application
By Location of Testing
By Country
Companies Profiled
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.